Nov 30, 2007 by Brian Orelli, PhDIncreased Potency Increases Stock PriceSirtris' preclinical data sends its stock up.
Nov 28, 2007 by Brian Orelli, PhDAbbott's Future as a Stent MakerThe FDA likes Abbott's new drug-eluting stent.
Nov 28, 2007 by Brian Orelli, PhDDrugmakers Spinning Their WheelsThe FDA isn't completely to blame for fewer new drug approvals.
Nov 28, 2007 by Brian Orelli, PhDStem Your Expectations of Stem-Cell DiscoveriesMaking "stem" cells out of skin cells isn't all it's cracked up to be.
Nov 27, 2007 by Brian Orelli, PhDSecond Chance for Merck's MEVACORThe rights for an OTC version of the drug are licensed to Glaxo.
Nov 27, 2007 by Brian Orelli, PhDPloughing Into Acquisition RewardsSchering-Plough reaps its first New Drug Application from its purchase of Organon.
Nov 26, 2007 by Brian Orelli, PhDJohnson & Johnson Reorganizes -- Who Wins?J&J's internal shuffle will help other companies.
Nov 23, 2007 by Brian Orelli, PhDAlmost at ParPar Pharmaceutical is almost caught up in releasing earnings for 2007.
Nov 21, 2007 by Brian Orelli, PhDBlack Friday Bargain Stock: Dr. Reddy's LaboratoriesGrowth is slowing, but is it enough to justify the drop in price?
Nov 21, 2007 by Brian Orelli, PhDPhase 2 Data to Sink Your Teeth IntoNovo Nordisk releases encouraging data about its weight-loss/diabetes drug, liraglutide.
Nov 21, 2007 by Brian Orelli, PhDDepression Hits BiovailAn FDA decision on Biovail's depression drug could be six months away.
Nov 21, 2007 by Brian Orelli, PhDVertex Skips a BeatSafety concerns force Vertex and Merck to stop enrolling subjects for clinical trial.
Nov 20, 2007 by Brian Orelli, PhDExplaining Onyx Pharmaceuticals' Sell-OffThe FDA approved Nexavar as a treatment for liver cancer. So what do investors do?
Nov 20, 2007 by Brian Orelli, PhDCelgene Buys a Sales ForceThe pharmaceutical acquires Pharmion for $2.9 billion.
Nov 19, 2007 by Brian Orelli, PhDGenetic Tests: Future or Fad?Genetic test makers start new services, but will people buy them?
Nov 16, 2007 by Brian Orelli, PhDWeighing In on Amylin's Drug CombinationPhase 2 looks good, but phase 3 actually counts.
Nov 15, 2007 by Brian Orelli, PhDSlowing the Cash Burn Bloody NoseNastech cuts costs and spins off a pre-clinical RNAi venture.
Nov 15, 2007 by Brian Orelli, PhDJohn Edwards' Not-So-Bad PlanHis plan for patents could work -- with the right incentive.
